nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—bone cancer	0.413	0.98	CbGbCtD
Orlistat—CYP3A4—bone cancer	0.401	1	CbGaD
Orlistat—CYP3A4—Doxorubicin—bone cancer	0.0086	0.0204	CbGbCtD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—T—bone cancer	0.00615	0.087	CbGpPWpGaD
Orlistat—FASN—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00494	0.0698	CbGpPWpGaD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—bone cancer	0.00387	1	CbGdCrCtD
Orlistat—DAGLA—tendon—bone cancer	0.00232	0.105	CbGeAlD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—MMP9—bone cancer	0.00214	0.0303	CbGpPWpGaD
Orlistat—PLA2G7—connective tissue—bone cancer	0.00212	0.0954	CbGeAlD
Orlistat—PNLIP—connective tissue—bone cancer	0.00186	0.0839	CbGeAlD
Orlistat—DAGLB—tendon—bone cancer	0.0018	0.0812	CbGeAlD
Orlistat—PLA2G7—tendon—bone cancer	0.00146	0.0656	CbGeAlD
Orlistat—PLA2G7—Metabolism of proteins—MOGS—bone cancer	0.00145	0.0205	CbGpPWpGaD
Orlistat—PLA2G7—bone marrow—bone cancer	0.00141	0.0635	CbGeAlD
Orlistat—PLA2G7—spinal cord—bone cancer	0.0014	0.0632	CbGeAlD
Orlistat—DAGLB—G alpha (q) signalling events—GRM1—bone cancer	0.00138	0.0196	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—GRM1—bone cancer	0.00138	0.0196	CbGpPWpGaD
Orlistat—ABHD16A—tendon—bone cancer	0.00137	0.0615	CbGeAlD
Orlistat—FASN—p73 transcription factor network—WT1—bone cancer	0.00134	0.0189	CbGpPWpGaD
Orlistat—ABHD16A—bone marrow—bone cancer	0.00132	0.0596	CbGeAlD
Orlistat—ABHD16A—spinal cord—bone cancer	0.00132	0.0593	CbGeAlD
Orlistat—ABHD12—tendon—bone cancer	0.00128	0.0577	CbGeAlD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00124	0.0175	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00124	0.0175	CbGpPWpGaD
Orlistat—ABHD12—spinal cord—bone cancer	0.00123	0.0556	CbGeAlD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	0.0012	0.0169	CbGpPWpGaD
Orlistat—PLA2G4A—ADP signalling through P2Y purinoceptor 1—GNA11—bone cancer	0.00112	0.0159	CbGpPWpGaD
Orlistat—FASN—spinal cord—bone cancer	0.00104	0.0467	CbGeAlD
Orlistat—FASN—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.00103	0.0146	CbGpPWpGaD
Orlistat—PLA2G4A—Signal amplification—GNA11—bone cancer	0.000945	0.0134	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—GNA11—bone cancer	0.000892	0.0126	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—GNA11—bone cancer	0.000892	0.0126	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000853	0.0121	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000853	0.0121	CbGpPWpGaD
Orlistat—FASN—Integration of energy metabolism—GNA11—bone cancer	0.000836	0.0118	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000798	0.0113	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000798	0.0113	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000797	0.0113	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—TUBB4B—bone cancer	0.000795	0.0112	CbGpPWpGaD
Orlistat—FASN—p73 transcription factor network—BRCA2—bone cancer	0.00079	0.0112	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00078	0.011	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00078	0.011	CbGpPWpGaD
Orlistat—PLA2G4A—connective tissue—bone cancer	0.000751	0.0338	CbGeAlD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000708	0.01	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000708	0.01	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—TUBB2A—bone cancer	0.000686	0.0097	CbGpPWpGaD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	0.000658	0.0093	CbGpPWpGaD
Orlistat—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00059	0.00835	CbGpPWpGaD
Orlistat—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000555	0.00785	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—GNA11—bone cancer	0.000536	0.00758	CbGpPWpGaD
Orlistat—PLA2G4A—tendon—bone cancer	0.000516	0.0233	CbGeAlD
Orlistat—FASN—p73 transcription factor network—RB1—bone cancer	0.000509	0.0072	CbGpPWpGaD
Orlistat—PLA2G4A—bone marrow—bone cancer	0.0005	0.0225	CbGeAlD
Orlistat—PLA2G4A—spinal cord—bone cancer	0.000498	0.0224	CbGeAlD
Orlistat—PLA2G7—Metabolism of proteins—EIF2S1—bone cancer	0.000479	0.00677	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—GRM4—bone cancer	0.000455	0.00643	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—RGS1—bone cancer	0.000455	0.00643	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—RGS1—bone cancer	0.000455	0.00643	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—GRM4—bone cancer	0.000455	0.00643	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—SPARC—bone cancer	0.00044	0.00622	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SPARC—bone cancer	0.00044	0.00622	CbGpPWpGaD
Orlistat—FASN—p73 transcription factor network—MDM2—bone cancer	0.000434	0.00614	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—NDUFA12—bone cancer	0.000429	0.00607	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—GRM4—bone cancer	0.000413	0.00584	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—RGS1—bone cancer	0.000413	0.00584	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—GRM4—bone cancer	0.000413	0.00584	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—RGS1—bone cancer	0.000413	0.00584	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—GNA11—bone cancer	0.000402	0.00569	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—GNA11—bone cancer	0.000402	0.00569	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—GRM1—bone cancer	0.000395	0.00558	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—GRM1—bone cancer	0.000395	0.00558	CbGpPWpGaD
Orlistat—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00039	0.00551	CbGpPWpGaD
Orlistat—FASN—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000387	0.00548	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—IL3—bone cancer	0.000365	0.00516	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IL3—bone cancer	0.000365	0.00516	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—GRM1—bone cancer	0.000358	0.00507	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—GRM1—bone cancer	0.000358	0.00507	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—NT5C3A—bone cancer	0.000356	0.00503	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000344	0.00487	CbGpPWpGaD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000319	0.00451	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000311	0.00439	CbGpPWpGaD
Orlistat—FASN—Metabolism—NDUFA12—bone cancer	0.000304	0.0043	CbGpPWpGaD
Orlistat—Increased appetite—Epirubicin—bone cancer	0.000288	0.00358	CcSEcCtD
Orlistat—Diabetes mellitus—Doxorubicin—bone cancer	0.000288	0.00357	CcSEcCtD
Orlistat—Menopausal symptoms—Epirubicin—bone cancer	0.000286	0.00356	CcSEcCtD
Orlistat—Malaise—Cisplatin—bone cancer	0.000286	0.00355	CcSEcCtD
Orlistat—PLA2G4A—PDGF Pathway—JUN—bone cancer	0.000285	0.00403	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000284	0.00401	CbGpPWpGaD
Orlistat—Dermatitis bullous—Epirubicin—bone cancer	0.000283	0.00352	CcSEcCtD
Orlistat—Hepatic failure—Doxorubicin—bone cancer	0.000278	0.00346	CcSEcCtD
Orlistat—Eczema—Doxorubicin—bone cancer	0.000278	0.00346	CcSEcCtD
Orlistat—FASN—AMPK Signaling—TP53—bone cancer	0.000278	0.00393	CbGpPWpGaD
Orlistat—Hypoglycaemia—Epirubicin—bone cancer	0.000277	0.00344	CcSEcCtD
Orlistat—Convulsion—Cisplatin—bone cancer	0.000275	0.00341	CcSEcCtD
Orlistat—Osteoarthritis—Epirubicin—bone cancer	0.00027	0.00336	CcSEcCtD
Orlistat—Myalgia—Cisplatin—bone cancer	0.00027	0.00335	CcSEcCtD
Orlistat—Anxiety—Cisplatin—bone cancer	0.000269	0.00334	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000268	0.00333	CcSEcCtD
Orlistat—Discomfort—Cisplatin—bone cancer	0.000267	0.00331	CcSEcCtD
Orlistat—Increased appetite—Doxorubicin—bone cancer	0.000266	0.00331	CcSEcCtD
Orlistat—Menopausal symptoms—Doxorubicin—bone cancer	0.000265	0.00329	CcSEcCtD
Orlistat—Dermatitis bullous—Doxorubicin—bone cancer	0.000262	0.00325	CcSEcCtD
Orlistat—Breast disorder—Methotrexate—bone cancer	0.000261	0.00324	CcSEcCtD
Orlistat—PLA2G4A—Arachidonic acid metabolism—PTGS2—bone cancer	0.000259	0.00366	CbGpPWpGaD
Orlistat—Oedema—Cisplatin—bone cancer	0.000259	0.00322	CcSEcCtD
Orlistat—Anaphylactic shock—Cisplatin—bone cancer	0.000259	0.00322	CcSEcCtD
Orlistat—Infection—Cisplatin—bone cancer	0.000257	0.00319	CcSEcCtD
Orlistat—Hypoglycaemia—Doxorubicin—bone cancer	0.000256	0.00319	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—GNA11—bone cancer	0.000254	0.0036	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—GNA11—bone cancer	0.000254	0.0036	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000254	0.00359	CbGpPWpGaD
Orlistat—Nervous system disorder—Cisplatin—bone cancer	0.000254	0.00315	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—SMO—bone cancer	0.000252	0.00357	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—SMO—bone cancer	0.000252	0.00357	CbGpPWpGaD
Orlistat—FASN—Metabolism—NT5C3A—bone cancer	0.000252	0.00356	CbGpPWpGaD
Orlistat—Skin disorder—Cisplatin—bone cancer	0.000251	0.00312	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—bone cancer	0.00025	0.00311	CcSEcCtD
Orlistat—Hyperhidrosis—Cisplatin—bone cancer	0.00025	0.00311	CcSEcCtD
Orlistat—Asthma—Methotrexate—bone cancer	0.00025	0.0031	CcSEcCtD
Orlistat—Dry skin—Epirubicin—bone cancer	0.000248	0.00308	CcSEcCtD
Orlistat—Abdominal pain upper—Epirubicin—bone cancer	0.000247	0.00307	CcSEcCtD
Orlistat—Hypokalaemia—Epirubicin—bone cancer	0.000246	0.00306	CcSEcCtD
Orlistat—Pancreatitis—Methotrexate—bone cancer	0.000245	0.00304	CcSEcCtD
Orlistat—Breast disorder—Epirubicin—bone cancer	0.000244	0.00304	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—GRM4—bone cancer	0.000244	0.00345	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RGS1—bone cancer	0.000244	0.00345	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—GRM4—bone cancer	0.000244	0.00345	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RGS1—bone cancer	0.000244	0.00345	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—MMP2—bone cancer	0.000242	0.00342	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000241	0.00341	CbGpPWpGaD
Orlistat—Abdominal discomfort—Methotrexate—bone cancer	0.000239	0.00297	CcSEcCtD
Orlistat—DAGLB—Hemostasis—PLAU—bone cancer	0.000239	0.00338	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—PLAU—bone cancer	0.000239	0.00338	CbGpPWpGaD
Orlistat—Gastritis—Epirubicin—bone cancer	0.000239	0.00297	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000236	0.00293	CcSEcCtD
Orlistat—Abdominal distension—Epirubicin—bone cancer	0.000235	0.00292	CcSEcCtD
Orlistat—Asthma—Epirubicin—bone cancer	0.000234	0.0029	CcSEcCtD
Orlistat—Influenza—Epirubicin—bone cancer	0.000234	0.0029	CcSEcCtD
Orlistat—Paraesthesia—Cisplatin—bone cancer	0.000232	0.00289	CcSEcCtD
Orlistat—Upper respiratory tract infection—Methotrexate—bone cancer	0.000232	0.00288	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—GNA11—bone cancer	0.000231	0.00326	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—GNA11—bone cancer	0.000231	0.00326	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—IL3—bone cancer	0.00023	0.00326	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—IL3—bone cancer	0.00023	0.00326	CbGpPWpGaD
Orlistat—Dry skin—Doxorubicin—bone cancer	0.000229	0.00285	CcSEcCtD
Orlistat—Pancreatitis—Epirubicin—bone cancer	0.000229	0.00285	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—bone cancer	0.000228	0.00284	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—bone cancer	0.000228	0.00283	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000227	0.00321	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000227	0.00321	CbGpPWpGaD
Orlistat—Breast disorder—Doxorubicin—bone cancer	0.000226	0.00281	CcSEcCtD
Orlistat—Decreased appetite—Cisplatin—bone cancer	0.000225	0.0028	CcSEcCtD
Orlistat—Gastrointestinal disorder—Cisplatin—bone cancer	0.000223	0.00278	CcSEcCtD
Orlistat—Infestation—Methotrexate—bone cancer	0.000223	0.00277	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—bone cancer	0.000223	0.00277	CcSEcCtD
Orlistat—Depression—Methotrexate—bone cancer	0.000222	0.00276	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—bone cancer	0.000221	0.00275	CcSEcCtD
Orlistat—Pain—Cisplatin—bone cancer	0.000221	0.00275	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00022	0.00311	CbGpPWpGaD
Orlistat—Renal failure—Methotrexate—bone cancer	0.000219	0.00272	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—bone cancer	0.000218	0.00271	CcSEcCtD
Orlistat—Upper respiratory tract infection—Epirubicin—bone cancer	0.000217	0.0027	CcSEcCtD
Orlistat—Asthma—Doxorubicin—bone cancer	0.000216	0.00269	CcSEcCtD
Orlistat—Influenza—Doxorubicin—bone cancer	0.000216	0.00269	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000215	0.00304	CbGpPWpGaD
Orlistat—Feeling abnormal—Cisplatin—bone cancer	0.000213	0.00265	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—bone cancer	0.000212	0.00263	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—GRM1—bone cancer	0.000212	0.00299	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—GRM1—bone cancer	0.000212	0.00299	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Methotrexate—bone cancer	0.00021	0.00262	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—IL3—bone cancer	0.000209	0.00296	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL3—bone cancer	0.000209	0.00296	CbGpPWpGaD
Orlistat—Infestation—Epirubicin—bone cancer	0.000208	0.00259	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—bone cancer	0.000208	0.00259	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000205	0.0029	CbGpPWpGaD
Orlistat—Renal failure—Epirubicin—bone cancer	0.000205	0.00255	CcSEcCtD
Orlistat—Body temperature increased—Cisplatin—bone cancer	0.000204	0.00254	CcSEcCtD
Orlistat—Neuropathy peripheral—Epirubicin—bone cancer	0.000204	0.00254	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—bone cancer	0.000202	0.00252	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—RGS1—bone cancer	0.000202	0.00286	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—GRM4—bone cancer	0.000202	0.00286	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000201	0.0025	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—bone cancer	0.000201	0.0025	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.0002	0.00283	CbGpPWpGaD
Orlistat—Hepatitis—Methotrexate—bone cancer	0.0002	0.00248	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—bone cancer	0.0002	0.00248	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	0.000199	0.00282	CbGpPWpGaD
Orlistat—Pharyngitis—Methotrexate—bone cancer	0.000198	0.00247	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000197	0.00279	CbGpPWpGaD
Orlistat—Urinary tract disorder—Methotrexate—bone cancer	0.000197	0.00245	CcSEcCtD
Orlistat—Hepatobiliary disease—Epirubicin—bone cancer	0.000197	0.00245	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000196	0.00278	CbGpPWpGaD
Orlistat—Urethral disorder—Methotrexate—bone cancer	0.000196	0.00243	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—MMP2—bone cancer	0.000196	0.00277	CbGpPWpGaD
Orlistat—Sinusitis—Epirubicin—bone cancer	0.000195	0.00243	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—JUN—bone cancer	0.000194	0.00274	CbGpPWpGaD
Orlistat—Infestation NOS—Doxorubicin—bone cancer	0.000193	0.0024	CcSEcCtD
Orlistat—Infestation—Doxorubicin—bone cancer	0.000193	0.0024	CcSEcCtD
Orlistat—Hypersensitivity—Cisplatin—bone cancer	0.000191	0.00237	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—bone cancer	0.000189	0.00236	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—bone cancer	0.000189	0.00235	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—bone cancer	0.000188	0.00234	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—bone cancer	0.000187	0.00233	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—JUN—bone cancer	0.000187	0.00264	CbGpPWpGaD
Orlistat—Hepatitis—Epirubicin—bone cancer	0.000187	0.00232	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—bone cancer	0.000187	0.00232	CcSEcCtD
Orlistat—PNLIP—Disease—ENO2—bone cancer	0.000186	0.00263	CbGpPWpGaD
Orlistat—Asthenia—Cisplatin—bone cancer	0.000186	0.00231	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—bone cancer	0.000186	0.00231	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—bone cancer	0.000185	0.0023	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—bone cancer	0.000184	0.00229	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—bone cancer	0.000183	0.00228	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—bone cancer	0.000182	0.00227	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—MMP9—bone cancer	0.000182	0.00257	CbGpPWpGaD
Orlistat—Sinusitis—Doxorubicin—bone cancer	0.000181	0.00225	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—bone cancer	0.00018	0.00224	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—bone cancer	0.00018	0.00224	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000178	0.00252	CbGpPWpGaD
Orlistat—Diarrhoea—Cisplatin—bone cancer	0.000177	0.0022	CcSEcCtD
Orlistat—Alopecia—Methotrexate—bone cancer	0.000177	0.00219	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—GRM1—bone cancer	0.000175	0.00248	CbGpPWpGaD
Orlistat—Mental disorder—Methotrexate—bone cancer	0.000175	0.00218	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—bone cancer	0.000174	0.00216	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—bone cancer	0.000174	0.00216	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—bone cancer	0.000173	0.00215	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—bone cancer	0.000173	0.00215	CcSEcCtD
Orlistat—PNLIP—Disease—DHFR—bone cancer	0.000173	0.00244	CbGpPWpGaD
Orlistat—Pharyngitis—Doxorubicin—bone cancer	0.000172	0.00213	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—bone cancer	0.000171	0.00212	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—bone cancer	0.00017	0.00212	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—bone cancer	0.00017	0.00212	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—bone cancer	0.00017	0.00211	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—bone cancer	0.000169	0.0021	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—bone cancer	0.000169	0.00209	CcSEcCtD
Orlistat—Back pain—Methotrexate—bone cancer	0.000168	0.00209	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000167	0.00236	CbGpPWpGaD
Orlistat—Alopecia—Epirubicin—bone cancer	0.000165	0.00205	CcSEcCtD
Orlistat—Vomiting—Cisplatin—bone cancer	0.000164	0.00204	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—bone cancer	0.000164	0.00204	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—bone cancer	0.000164	0.00204	CcSEcCtD
Orlistat—Rash—Cisplatin—bone cancer	0.000163	0.00203	CcSEcCtD
Orlistat—Dermatitis—Cisplatin—bone cancer	0.000163	0.00203	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—bone cancer	0.000163	0.00202	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—bone cancer	0.000161	0.00201	CcSEcCtD
Orlistat—Flatulence—Epirubicin—bone cancer	0.00016	0.00199	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—bone cancer	0.000159	0.00198	CcSEcCtD
Orlistat—Back pain—Epirubicin—bone cancer	0.000157	0.00196	CcSEcCtD
Orlistat—Malaise—Methotrexate—bone cancer	0.000157	0.00195	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—bone cancer	0.000156	0.00195	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—bone cancer	0.000156	0.00194	CcSEcCtD
Orlistat—Vertigo—Methotrexate—bone cancer	0.000156	0.00194	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—bone cancer	0.000156	0.00194	CcSEcCtD
Orlistat—PNLIP—Metabolism—ENO2—bone cancer	0.000156	0.0022	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—BRAF—bone cancer	0.000154	0.00218	CbGpPWpGaD
Orlistat—Nausea—Cisplatin—bone cancer	0.000154	0.00191	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—bone cancer	0.000153	0.00191	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—bone cancer	0.000153	0.0019	CcSEcCtD
Orlistat—Cough—Methotrexate—bone cancer	0.000152	0.00189	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—bone cancer	0.000152	0.00188	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—bone cancer	0.000151	0.00188	CcSEcCtD
Orlistat—Convulsion—Methotrexate—bone cancer	0.000151	0.00187	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—bone cancer	0.000151	0.00187	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—SMO—bone cancer	0.000149	0.00211	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SMO—bone cancer	0.000149	0.00211	CbGpPWpGaD
Orlistat—Flatulence—Doxorubicin—bone cancer	0.000148	0.00184	CcSEcCtD
Orlistat—Chest pain—Methotrexate—bone cancer	0.000148	0.00184	CcSEcCtD
Orlistat—Myalgia—Methotrexate—bone cancer	0.000148	0.00184	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—bone cancer	0.000147	0.00183	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000147	0.00183	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—EGFR—bone cancer	0.000147	0.00208	CbGpPWpGaD
Orlistat—Malaise—Epirubicin—bone cancer	0.000147	0.00182	CcSEcCtD
Orlistat—Discomfort—Methotrexate—bone cancer	0.000146	0.00182	CcSEcCtD
Orlistat—Vertigo—Epirubicin—bone cancer	0.000146	0.00182	CcSEcCtD
Orlistat—Back pain—Doxorubicin—bone cancer	0.000146	0.00181	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—bone cancer	0.000145	0.0018	CcSEcCtD
Orlistat—PNLIP—Metabolism—DHFR—bone cancer	0.000145	0.00204	CbGpPWpGaD
Orlistat—Palpitations—Epirubicin—bone cancer	0.000144	0.00179	CcSEcCtD
Orlistat—Cough—Epirubicin—bone cancer	0.000142	0.00177	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—bone cancer	0.000142	0.00176	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—bone cancer	0.000142	0.00176	CcSEcCtD
Orlistat—Convulsion—Epirubicin—bone cancer	0.000141	0.00175	CcSEcCtD
Orlistat—Infection—Methotrexate—bone cancer	0.000141	0.00175	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—bone cancer	0.00014	0.00174	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—bone cancer	0.000139	0.00173	CcSEcCtD
Orlistat—Myalgia—Epirubicin—bone cancer	0.000139	0.00172	CcSEcCtD
Orlistat—Chest pain—Epirubicin—bone cancer	0.000139	0.00172	CcSEcCtD
Orlistat—Anxiety—Epirubicin—bone cancer	0.000138	0.00172	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—bone cancer	0.000138	0.00171	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000138	0.00171	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—bone cancer	0.000137	0.00171	CcSEcCtD
Orlistat—Discomfort—Epirubicin—bone cancer	0.000137	0.0017	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—GNA11—bone cancer	0.000136	0.00193	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—GNA11—bone cancer	0.000136	0.00193	CbGpPWpGaD
Orlistat—Malaise—Doxorubicin—bone cancer	0.000136	0.00169	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—bone cancer	0.000136	0.00168	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—bone cancer	0.000135	0.00168	CcSEcCtD
Orlistat—PNLIP—Metabolism—GNA11—bone cancer	0.000135	0.00191	CbGpPWpGaD
Orlistat—Palpitations—Doxorubicin—bone cancer	0.000133	0.00165	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—bone cancer	0.000133	0.00165	CcSEcCtD
Orlistat—Oedema—Epirubicin—bone cancer	0.000133	0.00165	CcSEcCtD
Orlistat—Infection—Epirubicin—bone cancer	0.000132	0.00164	CcSEcCtD
Orlistat—FASN—Disease—ENO2—bone cancer	0.000132	0.00186	CbGpPWpGaD
Orlistat—Cough—Doxorubicin—bone cancer	0.000131	0.00163	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—bone cancer	0.00013	0.00162	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—NDUFA12—bone cancer	0.00013	0.00184	CbGpPWpGaD
Orlistat—Nervous system disorder—Epirubicin—bone cancer	0.00013	0.00162	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000129	0.00161	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—bone cancer	0.000129	0.0016	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—bone cancer	0.000128	0.0016	CcSEcCtD
Orlistat—Insomnia—Methotrexate—bone cancer	0.000128	0.0016	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—bone cancer	0.000128	0.00159	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—bone cancer	0.000128	0.00159	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—bone cancer	0.000128	0.00159	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—bone cancer	0.000127	0.00158	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000127	0.00158	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—ATF1—bone cancer	0.000127	0.00179	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ATF1—bone cancer	0.000127	0.00179	CbGpPWpGaD
Orlistat—Discomfort—Doxorubicin—bone cancer	0.000127	0.00157	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—bone cancer	0.000125	0.00156	CcSEcCtD
Orlistat—PNLIP—Disease—TGFBR2—bone cancer	0.000125	0.00177	CbGpPWpGaD
Orlistat—Dyspepsia—Methotrexate—bone cancer	0.000125	0.00155	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000124	0.00175	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL3—bone cancer	0.000124	0.00175	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL3—bone cancer	0.000124	0.00175	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SMO—bone cancer	0.000124	0.00175	CbGpPWpGaD
Orlistat—Decreased appetite—Methotrexate—bone cancer	0.000123	0.00153	CcSEcCtD
Orlistat—Oedema—Doxorubicin—bone cancer	0.000123	0.00153	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—bone cancer	0.000123	0.00153	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—bone cancer	0.000123	0.00152	CcSEcCtD
Orlistat—PNLIP—Metabolism—CYP3A4—bone cancer	0.000123	0.00173	CbGpPWpGaD
Orlistat—Fatigue—Methotrexate—bone cancer	0.000122	0.00152	CcSEcCtD
Orlistat—FASN—Disease—DHFR—bone cancer	0.000122	0.00173	CbGpPWpGaD
Orlistat—Infection—Doxorubicin—bone cancer	0.000122	0.00152	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000122	0.00172	CbGpPWpGaD
Orlistat—Pain—Methotrexate—bone cancer	0.000121	0.00151	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000121	0.0015	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—bone cancer	0.000121	0.0015	CcSEcCtD
Orlistat—Insomnia—Epirubicin—bone cancer	0.00012	0.00149	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—bone cancer	0.000119	0.00148	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—bone cancer	0.000119	0.00148	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—bone cancer	0.000119	0.00148	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—bone cancer	0.000117	0.00145	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—bone cancer	0.000117	0.00145	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—bone cancer	0.000116	0.00144	CcSEcCtD
Orlistat—Decreased appetite—Epirubicin—bone cancer	0.000115	0.00144	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—bone cancer	0.000115	0.00143	CcSEcCtD
Orlistat—Fatigue—Epirubicin—bone cancer	0.000115	0.00142	CcSEcCtD
Orlistat—Pain—Epirubicin—bone cancer	0.000114	0.00141	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—GNA11—bone cancer	0.000113	0.0016	CbGpPWpGaD
Orlistat—Urticaria—Methotrexate—bone cancer	0.000113	0.0014	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—bone cancer	0.000112	0.0014	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—bone cancer	0.000112	0.0014	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—JUN—bone cancer	0.000112	0.00159	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000112	0.00139	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—bone cancer	0.000111	0.00138	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—SPARC—bone cancer	0.000111	0.00156	CbGpPWpGaD
Orlistat—Paraesthesia—Doxorubicin—bone cancer	0.00011	0.00137	CcSEcCtD
Orlistat—FASN—Metabolism—ENO2—bone cancer	0.00011	0.00156	CbGpPWpGaD
Orlistat—Feeling abnormal—Epirubicin—bone cancer	0.000109	0.00136	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—bone cancer	0.000109	0.00135	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—bone cancer	0.000108	0.00135	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—NT5C3A—bone cancer	0.000108	0.00153	CbGpPWpGaD
Orlistat—Decreased appetite—Doxorubicin—bone cancer	0.000107	0.00133	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000106	0.00132	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—bone cancer	0.000106	0.00132	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—TGFBR2—bone cancer	0.000106	0.0015	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFBR2—bone cancer	0.000106	0.0015	CbGpPWpGaD
Orlistat—Urticaria—Epirubicin—bone cancer	0.000106	0.00131	CcSEcCtD
Orlistat—Pain—Doxorubicin—bone cancer	0.000105	0.00131	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—ATF1—bone cancer	0.000105	0.00149	CbGpPWpGaD
Orlistat—Abdominal pain—Epirubicin—bone cancer	0.000105	0.00131	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—bone cancer	0.000105	0.00131	CcSEcCtD
Orlistat—PNLIP—Metabolism—GSTP1—bone cancer	0.000105	0.00148	CbGpPWpGaD
Orlistat—Hypersensitivity—Methotrexate—bone cancer	0.000105	0.0013	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—GRM4—bone cancer	0.000104	0.00147	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RGS1—bone cancer	0.000104	0.00147	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL3—bone cancer	0.000102	0.00145	CbGpPWpGaD
Orlistat—FASN—Metabolism—DHFR—bone cancer	0.000102	0.00145	CbGpPWpGaD
Orlistat—Asthenia—Methotrexate—bone cancer	0.000102	0.00127	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—bone cancer	0.000101	0.00126	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—GNA11—bone cancer	0.000101	0.00143	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Doxorubicin—bone cancer	0.000101	0.00125	CcSEcCtD
Orlistat—Pruritus—Methotrexate—bone cancer	0.0001	0.00125	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—IGF1R—bone cancer	9.95e-05	0.00141	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IGF1R—bone cancer	9.95e-05	0.00141	CbGpPWpGaD
Orlistat—Hypersensitivity—Epirubicin—bone cancer	9.79e-05	0.00122	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—bone cancer	9.76e-05	0.00121	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—bone cancer	9.72e-05	0.00121	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—bone cancer	9.72e-05	0.00121	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—bone cancer	9.71e-05	0.00121	CcSEcCtD
Orlistat—DAGLA—Hemostasis—TP53—bone cancer	9.62e-05	0.00136	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—bone cancer	9.62e-05	0.00136	CbGpPWpGaD
Orlistat—FASN—Metabolism—GNA11—bone cancer	9.56e-05	0.00135	CbGpPWpGaD
Orlistat—Asthenia—Epirubicin—bone cancer	9.53e-05	0.00118	CcSEcCtD
Orlistat—Pruritus—Epirubicin—bone cancer	9.4e-05	0.00117	CcSEcCtD
Orlistat—Dizziness—Methotrexate—bone cancer	9.39e-05	0.00117	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	9.19e-05	0.0013	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL3—bone cancer	9.17e-05	0.0013	CbGpPWpGaD
Orlistat—Diarrhoea—Epirubicin—bone cancer	9.09e-05	0.00113	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—bone cancer	9.06e-05	0.00113	CcSEcCtD
Orlistat—Vomiting—Methotrexate—bone cancer	9.02e-05	0.00112	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—GRM1—bone cancer	9.01e-05	0.00127	CbGpPWpGaD
Orlistat—Rash—Methotrexate—bone cancer	8.95e-05	0.00111	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—bone cancer	8.94e-05	0.00111	CcSEcCtD
Orlistat—Headache—Methotrexate—bone cancer	8.89e-05	0.00111	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	8.86e-05	0.00125	CbGpPWpGaD
Orlistat—FASN—Disease—TGFBR2—bone cancer	8.85e-05	0.00125	CbGpPWpGaD
Orlistat—Asthenia—Doxorubicin—bone cancer	8.82e-05	0.0011	CcSEcCtD
Orlistat—Dizziness—Epirubicin—bone cancer	8.78e-05	0.00109	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—TGFBR2—bone cancer	8.76e-05	0.00124	CbGpPWpGaD
Orlistat—Pruritus—Doxorubicin—bone cancer	8.7e-05	0.00108	CcSEcCtD
Orlistat—FASN—Metabolism—CYP3A4—bone cancer	8.67e-05	0.00123	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.62e-05	0.00122	CbGpPWpGaD
Orlistat—PNLIP—Disease—KIT—bone cancer	8.54e-05	0.00121	CbGpPWpGaD
Orlistat—Vomiting—Epirubicin—bone cancer	8.45e-05	0.00105	CcSEcCtD
Orlistat—Nausea—Methotrexate—bone cancer	8.43e-05	0.00105	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—bone cancer	8.41e-05	0.00105	CcSEcCtD
Orlistat—Rash—Epirubicin—bone cancer	8.38e-05	0.00104	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—bone cancer	8.37e-05	0.00104	CcSEcCtD
Orlistat—Headache—Epirubicin—bone cancer	8.32e-05	0.00103	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—IGF1R—bone cancer	8.24e-05	0.00117	CbGpPWpGaD
Orlistat—Dizziness—Doxorubicin—bone cancer	8.13e-05	0.00101	CcSEcCtD
Orlistat—PNLIP—Disease—BRAF—bone cancer	8.03e-05	0.00113	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.99e-05	0.00113	CbGpPWpGaD
Orlistat—Nausea—Epirubicin—bone cancer	7.89e-05	0.000981	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—bone cancer	7.81e-05	0.000972	CcSEcCtD
Orlistat—Rash—Doxorubicin—bone cancer	7.75e-05	0.000963	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—bone cancer	7.74e-05	0.000963	CcSEcCtD
Orlistat—Headache—Doxorubicin—bone cancer	7.7e-05	0.000957	CcSEcCtD
Orlistat—FASN—Metabolism—GSTP1—bone cancer	7.41e-05	0.00105	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—bone cancer	7.3e-05	0.000908	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—KIT—bone cancer	7.22e-05	0.00102	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KIT—bone cancer	7.22e-05	0.00102	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—BRAF—bone cancer	6.78e-05	0.000959	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—BRAF—bone cancer	6.78e-05	0.000959	CbGpPWpGaD
Orlistat—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.72e-05	0.000951	CbGpPWpGaD
Orlistat—PNLIP—Disease—MDM2—bone cancer	6.72e-05	0.000951	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—bone cancer	6.57e-05	0.00093	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EGFR—bone cancer	6.57e-05	0.00093	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—bone cancer	6.48e-05	0.000917	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—SMO—bone cancer	6.35e-05	0.000898	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.28e-05	0.000888	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRM4—bone cancer	6.14e-05	0.000868	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RGS1—bone cancer	6.14e-05	0.000868	CbGpPWpGaD
Orlistat—FASN—Disease—KIT—bone cancer	6.04e-05	0.000854	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PLAU—bone cancer	6.02e-05	0.000851	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KIT—bone cancer	5.98e-05	0.000846	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GNA11—bone cancer	5.81e-05	0.000821	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MDM2—bone cancer	5.68e-05	0.000804	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MDM2—bone cancer	5.68e-05	0.000804	CbGpPWpGaD
Orlistat—FASN—Disease—BRAF—bone cancer	5.68e-05	0.000803	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—BRAF—bone cancer	5.62e-05	0.000795	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—bone cancer	5.43e-05	0.000768	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRM1—bone cancer	5.32e-05	0.000753	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.28e-05	0.000746	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL3—bone cancer	5.27e-05	0.000745	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—JUN—bone cancer	4.94e-05	0.000699	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—JUN—bone cancer	4.94e-05	0.000699	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—bone cancer	4.81e-05	0.00068	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—bone cancer	4.81e-05	0.00068	CbGpPWpGaD
Orlistat—FASN—Disease—MDM2—bone cancer	4.76e-05	0.000673	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ENO2—bone cancer	4.73e-05	0.000669	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MDM2—bone cancer	4.71e-05	0.000666	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—bone cancer	4.6e-05	0.00065	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—bone cancer	4.59e-05	0.000649	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—DHFR—bone cancer	4.39e-05	0.000621	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.36e-05	0.000616	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.3e-05	0.000608	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GNA11—bone cancer	4.1e-05	0.00058	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JUN—bone cancer	4.09e-05	0.000579	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—bone cancer	3.98e-05	0.000563	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—bone cancer	3.88e-05	0.000549	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—bone cancer	3.88e-05	0.000549	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—bone cancer	3.84e-05	0.000543	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMO—bone cancer	3.75e-05	0.00053	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP3A4—bone cancer	3.72e-05	0.000526	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.7e-05	0.000523	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNA11—bone cancer	3.43e-05	0.000485	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—bone cancer	3.26e-05	0.000461	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—bone cancer	3.26e-05	0.000461	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—bone cancer	3.25e-05	0.00046	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—bone cancer	3.22e-05	0.000455	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ATF1—bone cancer	3.19e-05	0.000451	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—bone cancer	3.18e-05	0.00045	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL3—bone cancer	3.11e-05	0.00044	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NDUFA12—bone cancer	3.05e-05	0.000432	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—bone cancer	2.7e-05	0.000382	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFBR2—bone cancer	2.66e-05	0.000376	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NT5C3A—bone cancer	2.53e-05	0.000358	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—bone cancer	2.5e-05	0.000354	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—bone cancer	2.42e-05	0.000342	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KIT—bone cancer	1.82e-05	0.000257	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—bone cancer	1.71e-05	0.000241	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—bone cancer	1.65e-05	0.000234	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—bone cancer	1.65e-05	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MDM2—bone cancer	1.43e-05	0.000202	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—bone cancer	1.24e-05	0.000176	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—bone cancer	1.21e-05	0.000171	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO2—bone cancer	1.11e-05	0.000157	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—DHFR—bone cancer	1.03e-05	0.000145	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—bone cancer	9.77e-06	0.000138	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNA11—bone cancer	9.61e-06	0.000136	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—bone cancer	8.2e-06	0.000116	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—bone cancer	7.45e-06	0.000105	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—bone cancer	3.86e-06	5.46e-05	CbGpPWpGaD
